Skip to content

PREVIEW

In the six months since our last report, vaccine news, ongoing stimulus, and strong economic indicators have changed the COVID-focused downturn narrative to one of recovery. The February 2021 reporting season has brought in the strongest earnings per share (EPS) revisions we have seen for Australian companies in 10 years.

Digesting the results, and translating these into earnings revisions, the market now expects that we will be back to pre-COVID levels of earnings within the next twelve months.

We are excited by the recovery, and what it means for our portfolios going forward. Based on our top-down analysis, fundamental views from our company engagements, and our big picture work, the future does look more positive, and there are good opportunities for Australian companies to thrive in a post-COVID world, but risks remain from the end of JobKeeper, inflation, zero rates and poor governance.

We would reiterate that it is important to be aware that Value spreads are narrowing as the economy rebounds, and to focus on Value style stocks while avoiding the expensive stocks and parts of the market that will be damaged by inflation.

For income focused investors, dividends from high quality companies will continue to be very compelling relative to other income asset class options available today, especially as worldwide stimulus is building inflationary pressures and steeping the yield curve.

In the full article (PDF), our team of Australian investment specialists, led by Reece Birtles, Martin Currie Australia's Chief Investment Officer, provide:

  • A top-down analytical review of the recent company reporting season;
  • insight into the key fundamental themes from our engagements with company boards and management;
  • analysis of Australia’s economic and market outlook; and
  • implications for investors in Australian equities.


IMPORTANT LEGAL INFORMATION

Information on this website is intended to be of general information only and does not constitute investment or financial product advice. It expresses no views as to the suitability of the products or services described as to the individual circumstances, objectives, financial situation, or needs of any investor. You should conduct your own investigation or consult a financial adviser before making any decision to invest. Please read the relevant Product Disclosure Statements (PDSs), and any associated reference documents before making an investment decision.

Neither Franklin Templeton Australia, nor any other company within the Franklin Templeton group guarantees the performance of any Fund, nor do they provide any guarantee in respect of the repayment of your capital. In accordance with the Design and Distribution Obligations, we maintain Target Market Determinations (TMD) for each of our Funds. All documents can be found via the Literature Page or by calling 1800 673 776. 

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.